Literature DB >> 31301097

Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.

Xuemei Li1, Jidan Zhou2, Ci Chu1, Qian You1, Renming Zhong2, Zhiyong Rao1, Wen Hu1.   

Abstract

BACKGROUND: The aim of this study is to assess the effect of home enteral nutrition (HEN) on the myelosuppression of patients with nasopharyngeal cancer (NPC) during the course of concurrent chemoradiotherapy (CCRT).
METHODS: A total of 18 outpatients with NPC administered oral nutritional supplementation intervention at home during the course of CCRT were designated as the HEN group, whereas 36 patients with NPC who had previously completed CCRT were retrospectively included as the control group. Patient Generated Subjective Global Assessment, body mass index (BMI), and blood test were evaluated prior to CCRT. During the course of CCRT, blood test was assessed every 2 weeks.
RESULTS: In male patients, hemoglobin (HB) and red blood cell were decreased (P < .05) in both HEN and control group after CCRT, whereas white blood cell (WBC) started to decrease since week 2 of CCRT in the control group but maintained in the HEN group which was significantly higher than the control (5.05 ± 1.29 vs 3.77 ± 1.5, P < .05). In female patients, HB and WBC were reduced in control group during CCRT, whereas these indicators also maintained in the HEN group. Surprisingly, all patients with lower BMI (<24 kg/m2 ) had a significant increase in platelet (PLT) after CCRT (200.78 ± 58.03 vs 253.00 ± 69.82, P < .05), while had steady HB and WBC values in the HEN group. At the end of CCRT, WBC and PLT of the HEN group were both higher than those in the control group (5.21 ± 1.07 vs 3.37 ± 1.52), (253.00 ± 69.82 vs 165.57 ± 59.56) (P < .05 for both). Our findings suggest that HEN is effective in preventing myelosuppression during CCRT for patients with NPC.
CONCLUSION: Our findings suggest that HEN is effective in preventing myelosuppression during CCRT for patients with NPC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemoradiotherapy; enteral nutrition; nasopharyngeal cancer; white blood cell

Year:  2019        PMID: 31301097     DOI: 10.1002/hed.25861

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

1.  The Effect of Omega-3 Enriched Oral Nutrition Supplement on Nutritional Indices and Quality of Life in Gastrointestinal Cancer Patients: A Randomized Clinical Trial.

Authors:  Eunbo Sim; Jin-Min Kim; Seung-Min Lee; Moon Jae Chung; Si Young Song; Eun Sun Kim; Hoon Jai Chun; Mi-Kyung Sung
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

2.  Implication of hsa_circ_0028007 in reinforcing migration, invasion, and chemo-tolerance of nasopharyngeal carcinoma cells.

Authors:  Dong Qiongna; Zhang Jiafeng; Hao Yalin; He Ping; Zhou Chuan; Jin Xiaojie; Zhao Miaomiao; Shao Yiting; Zhao Hui
Journal:  J Clin Lab Anal       Date:  2020-06-11       Impact factor: 2.352

Review 3.  Biomaterial-based strategies for maxillofacial tumour therapy and bone defect regeneration.

Authors:  Bowen Tan; Quan Tang; Yongjin Zhong; Yali Wei; Linfeng He; Yanting Wu; Jiabao Wu; Jinfeng Liao
Journal:  Int J Oral Sci       Date:  2021-03-16       Impact factor: 6.344

4.  Effects of Enteral Nutrition on Patients With Oesophageal Carcinoma Treated With Concurrent Chemoradiotherapy: A Prospective, Multicentre, Randomised, Controlled Study.

Authors:  Jiahua Lyu; Anhui Shi; Tao Li; Jie Li; Ren Zhao; Shuchai Zhu; Jianhua Wang; Ligang Xing; Daoke Yang; Conghua Xie; Liangfang Shen; Hailin Zhang; Guangying Zhu; Jing Wang; Wenyan Pan; Fang Li; Jinyi Lang; Hanping Shi
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

5.  Efficacy of Cereal-based Oral Nutrition Supplement on Nutritional Status, Inflammatory Cytokine Secretion and Quality of Life in Cancer Patients Under Cancer Therapy.

Authors:  Jin-Min Kim; Sung-Gil Hong; Bum-Seok Song; Hee-Jung Sohn; Hyunwook Baik; Mi-Kyung Sung
Journal:  J Cancer Prev       Date:  2020-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.